CIK 0001776111 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MBX Biosciences, Inc.
Sign in to watch- Ticker
- MBX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 3179893100
- Business address
- 11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46032
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $288,361
- in 2 filings
Net −$288,361. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-08 | Azoulay Salomon Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | +15,003 | 30,008 | ||
| 2026-05-06 | Azoulay Salomon Chief Medical Officer | Sale | −231 | $29.54 | $7K | 14,769 |
| 2026-05-06 | Hawryluk P. Kent President & CEO | Sale | −607 | $29.54 | $18K | 727,667 |
| 2026-05-01 | Hoerter Steven L. Director | Grant or award | +11,938 | 11,938 | ||
| 2026-05-01 | Hoerter Steven L. Director | Grant or award · Stock option (right to buy) | +74,249 | 74,249 | ||
| 2026-03-13 | Hawryluk P. Kent President & CEO | Purchase | +18,500 | $28.41 | $526K | 486,777 |
| 2026-02-26 | Hawryluk P. Kent President & CEO | Option exercise | +28,768 | $16.00 | $460K | 728,274 |
| 2026-02-26 | Hawryluk P. Kent President & CEO | Option exercise · Stock option (right to buy) | −28,768 | 91,668 | ||
| 2026-02-02 | Azoulay Salomon Chief Medical Officer | Grant or award | +15,000 | 15,000 | ||
| 2026-02-02 | Azoulay Salomon Chief Medical Officer | Grant or award · Stock option (right to buy) | +70,000 | 70,000 | ||
| 2026-02-02 | Bartram Richard Chief Financial Officer | Grant or award | +15,000 | 15,000 | ||
| 2026-02-02 | Bartram Richard Chief Financial Officer | Grant or award · Stock option (right to buy) | +70,000 | 70,000 | ||
| 2026-02-02 | Hawryluk P. Kent President & CEO | Grant or award | +35,250 | 699,506 | ||
| 2026-02-02 | Hawryluk P. Kent President & CEO | Grant or award · Stock option (right to buy) | +164,500 | 164,500 | ||
| 2026-01-20 | Stelzer Laurie Director | Grant or award · Stock option (right to buy) | +32,000 | 32,000 | ||
| 2025-11-22 | Hoerter Steven L. Director | Grant or award · Stock option (right to buy) | +0 | 0 | ||
| 2025-11-22 | Hoerter Steven L. Director | Grant or award · Stock option (right to buy) | +8,000 | 8,000 | ||
| 2025-11-06 | Hoerter Steven L. Director | Grant or award · Stock option (right to buy) | +33,751 | 33,751 | ||
| 2025-11-06 | Hoerter Steven L. Director | Grant or award · Stock option (right to buy) | +100,000 | 100,000 | ||
| 2025-10-24 | Hawryluk P. Kent President & CEO | Option exercise | +182,859 | $3.25 | $594K | 664,256 |
Page 2 of 9 · 164 trades